Drug Discovery

Takeda, Harrington to advance development of rare disease therapeutics

Takeda Pharmaceutical has entered into a multi-year partnership with Harrington Discovery Institute at University Hospitals in Cleveland, Ohio to advance the development of rare disease rherapeutics.

Gates Foundation leads $45.5m round for biotechnology firm Arsanis

Clinical-stage biopharmaceutical firm Arsanis has secured $45.5m in a Series D financing round led by the Bill & Melinda Gates Foundation.

Immune Pharmaceuticals licenses cancer treatment’s Latin America rights to Pint

Immune Pharmaceuticals has entered into a letter of intent with Pint Pharma regarding license and commercializion of Ceplene in Latin America.

Alpine Immune Sciences to merge with Nivalis Therapeutics

Alpine Immune Sciences has agreed to merge with a subsidiary of Nivalis Therapeutics in an all-stock transaction.

Lyndra secures $23m funding to develop therapeutic oral delivery platform

Lyndra has secured $23m Series A financing, led by Polaris Partners, with participation from Quark Venture and GF Securities, Yonghua Capital, Healthlink Capital, Suffolk Equity, Partners Healthcare among others.

PureTech Health launches new immuno-oncology programme

PureTech Health has launched a new immuno-oncology programme to develop monoclonal antibodies to target newly discovered immunosuppressive mechanisms in pancreatic cancer and other solid tumours.

Accenture, BioCelerate partner to advance biopharmaceutical innovation

Accenture and TransCelerate BioPharma's subsidiary BioCelerate have partnered to advance biopharmaceutical innovation through increased insights in research & development.

Eisai and Meiji enter into agreement for Parkinson’s disease drug in Asian countries

Eisai and Meiji Seika Pharma have entered into a license agreement for the commercialization of safinamide for Parkinson's disease treatment in Japan and Asia.

Sucampo Pharmaceuticals buys rare disease firm Vtesse

Sucampo Pharmaceuticals has acquired rare disease company Vtesse for upfront consideration of $200m.